[177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial

The Lancet · Published 2026-07-01 · DOI 10.1016/s0140-6736(26)00604-5

Authors (29)

Thomas Walter, Henning Jann, Catherine Ansquer, Emmanuel Deshayes, Rocio Garcia-Carbonero, Alexandre Teulé, Richard P Baum, Hein J Verberne, Jarosław B Ćwikła, Rajaventhan Srirajaskanthan, Louis de Mestier, Chiara M Grana, Andreas Buck, Dieter Hörsch, Marianne Pavel, Lawrence O Dierickx, Michael Michael, Jonathan Strosberg, Attila Kollár, Paula Jimenez-Fonseca, Anja Rinke, Maribel del Olmo-García, Anthime Flaus, Jorge Hernando, Andreas Kluge, Monika Breuninger, Serhii Melnyk, Konstantin Zhernosekov, Jaume Capdevila

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Walter, T., Jann, H., Ansquer, C., et al. (2026). [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(26)00604-5

Related articles